RT Journal Article
SR Electronic
T1 ERAAs for menopause treatment: Welcome the ‘designer estrogens’
JF Cleveland Clinic Journal of Medicine
JO Cleve Clin J Med
FD Cleveland Clinic
SP 463
OP 470
DO 10.3949/ccjm.84a.15140
VO 84
IS 6
A1 Hirsch, Heather D.
A1 Shih, Elim
A1 Thacker, Holly L.
YR 2017
UL http://www.ccjm.org/content/84/6/463.abstract
AB Estrogen receptor agonist-antagonists (ERAAs) selectively inhibit or stimulate estrogen-like action in targeted tissues. This review summarizes how ERAAs can be used in combination with an estrogen or alone to treat menopausal symptoms (vasomotor symptoms, genitourinary syndrome of menopause), breast cancer or the risk of breast cancer, osteopenia, osteoporosis, and other female midlife concerns.